EcoDrugPlus

Receptor Tyrosine-Protein Kinase Erbb-3

Ensembl ID : ENSELUG00000008353
Gene Symbol: LOC105008046
3 Cross references
207 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4

Ensembl ID : ENSELUG00000002509
Gene Symbol: LOC105023139
3 Cross references
243 Possible Orthologues:

Receptor-Type Tyrosine-Protein Phosphatase Beta

Ensembl ID : ENSELUG00000012231
Gene Symbol: LOC105023109
3 Cross references
194 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSELUG00000008551
Gene Symbol: RPTOR
3 Cross references
214 Possible Orthologues:

Renin

Ensembl ID : ENSELUG00000024611
Gene Symbol: LOC105007023
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSELUG00000020668
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-A

Ensembl ID : ENSELUG00000000650
Gene Symbol: LOC105024178
3 Cross references
220 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSELUG00000009433
Gene Symbol: RARB
3 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSELUG00000013678
Gene Symbol: LOC105021879
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSELUG00000007651
Gene Symbol: RARG
3 Cross references
371 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSELUG00000019908
Gene Symbol: RARG
3 Cross references
361 Possible Orthologues:

Ribosomal Protein L10

Ensembl ID : ENSELUG00000020689
Gene Symbol: RPL10
2 Cross references
408 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).